IL110566A - Stable aqueous solution of hybrid alpha-interferon - Google Patents

Stable aqueous solution of hybrid alpha-interferon

Info

Publication number
IL110566A
IL110566A IL11056694A IL11056694A IL110566A IL 110566 A IL110566 A IL 110566A IL 11056694 A IL11056694 A IL 11056694A IL 11056694 A IL11056694 A IL 11056694A IL 110566 A IL110566 A IL 110566A
Authority
IL
Israel
Prior art keywords
interferon
aqueous solution
stable aqueous
hybrid alpha
alpha
Prior art date
Application number
IL11056694A
Other languages
English (en)
Other versions
IL110566A0 (en
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939316849A external-priority patent/GB9316849D0/en
Priority claimed from GB9405879A external-priority patent/GB9405879D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL110566A0 publication Critical patent/IL110566A0/xx
Publication of IL110566A publication Critical patent/IL110566A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
IL11056694A 1993-08-13 1994-08-04 Stable aqueous solution of hybrid alpha-interferon IL110566A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939316849A GB9316849D0 (en) 1993-08-13 1993-08-13 Pharmaceutical compositions
GB9405879A GB9405879D0 (en) 1994-03-24 1994-03-24 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
IL110566A0 IL110566A0 (en) 1995-01-24
IL110566A true IL110566A (en) 1999-12-22

Family

ID=26303371

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11056694A IL110566A (en) 1993-08-13 1994-08-04 Stable aqueous solution of hybrid alpha-interferon

Country Status (19)

Country Link
US (1) US5609868A (pt)
EP (1) EP0641567B1 (pt)
JP (1) JP3745395B2 (pt)
KR (1) KR100351495B1 (pt)
AT (1) ATE190498T1 (pt)
AU (1) AU679233B2 (pt)
CA (1) CA2129921C (pt)
CY (1) CY2230B1 (pt)
DE (1) DE69423402T2 (pt)
DK (1) DK0641567T3 (pt)
ES (1) ES2144034T3 (pt)
FI (1) FI111222B (pt)
GR (1) GR3033239T3 (pt)
HU (1) HU224613B1 (pt)
IL (1) IL110566A (pt)
NO (1) NO315843B1 (pt)
NZ (1) NZ264218A (pt)
PT (1) PT641567E (pt)
TW (1) TW249202B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020102236A1 (en) * 1994-12-08 2002-08-01 Taylor Peter William Liposomal interferon hybrid compositions
US20030190307A1 (en) * 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
CA2275890C (en) * 1996-12-24 2011-11-01 Biogen, Inc. Stable liquid interferon formulations
KR19990075253A (ko) * 1998-03-18 1999-10-15 성재갑 약학적으로 안정한 인터페론 제
US6685933B1 (en) * 1998-07-28 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Interferon α hybrids
ES2167189B1 (es) * 1999-12-17 2003-04-01 Lipotec Sa Formulacion farmaceutica estable para la administracion intravenosa o intramuscular, de principios activos peptidicos
PT1343518E (pt) * 2000-11-07 2009-08-03 Novartis Vaccines & Diagnostic Composições de interferão estabilizadas
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
AR044302A1 (es) * 2003-05-13 2005-09-07 Ares Trading Sa Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
EA014157B1 (ru) * 2005-06-29 2010-10-29 Йеда Рисерч Энд Дивелопмент Ко. Лтд. РЕКОМБИНАНТНЫЕ МУТАНТЫ ИНТЕРФЕРОНА α2 (IFNα2)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59196823A (ja) * 1983-04-20 1984-11-08 Sunstar Inc 皮膚および粘膜の真菌症治療用外用剤
US4855238A (en) * 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
MA20647A1 (fr) * 1985-03-25 1986-10-01 Schering Corp Compositions stables a base d'interferon-gamma
ATE78262T1 (de) * 1985-06-11 1992-08-15 Ciba Geigy Ag Hybrid-interferone.
US4847079A (en) * 1985-07-29 1989-07-11 Schering Corporation Biologically stable interferon compositions comprising thimerosal
IL88233A (en) * 1987-11-03 1993-08-18 Genentech Inc Gamma interferon formulation
EP0331635A3 (en) * 1988-02-29 1990-02-28 The Board of Regents of the University of Texas System Preparations for treating bladder cancer

Also Published As

Publication number Publication date
FI111222B (fi) 2003-06-30
CY2230B1 (en) 2003-04-18
DK0641567T3 (da) 2000-08-14
HUT68692A (en) 1995-07-28
EP0641567B1 (en) 2000-03-15
DE69423402D1 (de) 2000-04-20
TW249202B (pt) 1995-06-11
PT641567E (pt) 2000-08-31
ES2144034T3 (es) 2000-06-01
JPH07145070A (ja) 1995-06-06
NO942983L (no) 1995-02-14
IL110566A0 (en) 1995-01-24
CA2129921C (en) 2006-12-05
AU679233B2 (en) 1997-06-26
HU9402356D0 (en) 1994-10-28
KR950005325A (ko) 1995-03-20
FI943705A0 (fi) 1994-08-10
KR100351495B1 (ko) 2003-02-19
ATE190498T1 (de) 2000-04-15
JP3745395B2 (ja) 2006-02-15
CA2129921A1 (en) 1995-02-14
NO315843B1 (no) 2003-11-03
NZ264218A (en) 1995-07-26
AU6893994A (en) 1995-02-23
DE69423402T2 (de) 2000-08-03
EP0641567A1 (en) 1995-03-08
NO942983D0 (no) 1994-08-12
FI943705A (fi) 1995-02-14
HU224613B1 (hu) 2005-11-28
GR3033239T3 (en) 2000-09-29
US5609868A (en) 1997-03-11

Similar Documents

Publication Publication Date Title
MY113806A (en) Antiparasitic marcfortines and paraherquamides
ES2164731T3 (es) Suspension acuosa tixotropica de agentes fitoprotectores.
IL106677A0 (en) Novel 7-(substituted)-8-(substituted-9-(substituted amino)-6-demethyl-6-deoxytetracyclines
EP0562049A4 (en) Novel 4-arylpiperazines and 4-arylpiperidines
HU9503370D0 (en) N-alkylthio polyamine derivatives as radioprotective agents
TW249202B (pt)
GR3031781T3 (en) Antifungal sordaridin derivatives
IN179094B (pt)
DE69818261D1 (en) Hydroxycyclopentanone
ES2146606T3 (es) Metodo para limpiar alfombras.
TW231256B (pt)
ZA904671B (en) Hair treatment composition
EP0974347A4 (en) ANTIVIRAL AGENTS
NZ279396A (en) Octahydro-6-hetring[2,1-a][2]benzazepine disulphide derivatives
EP0978277A4 (en) ANTI-RHUMATISMAL AGENTS
EP0978281A4 (en) EYE DROPS
EP0994111A4 (en) TETRAHYDROFURANNE DERIVATIVES
EP0659752A4 (pt)

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees